🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Sunshine Guojian Pharmaceutical (Shanghai) clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Sunshine Guojian Pharmaceutical (Shanghai) as lead sponsor. Synced 26 Sep 2026
16Current trials
11Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Sunshine Guojian Pharmaceutical (Shanghai) is the lead sponsor of 16 current clinical trials in our China register. 11 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Bevacizumab, Calcium folinate and Capecitabine. The most-studied condition is Asthma.

ClinicalTrials.gov trials by status

  • Recruiting1169%
  • Not yet open319%
  • Active, closed213%

Trials by phase

  • Phase 3744%
  • Phase 2531%
  • Phase 1319%
  • Phase 1/216%
01

Clinical trials sponsored by Sunshine Guojian Pharmaceutical (Shanghai)

16 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
NCT07185269 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)
Phase 1/2 Recruiting 2025-09 China
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
NCT06493760 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer
Phase 2 Recruiting 2024-09 China
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
NCT07261644 · ClinicalTrials.gov ↗ · Ankylosing Spondylitis
Phase 3 Recruiting 2025-11 China
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors
NCT06390774 · ClinicalTrials.gov ↗ · Locally Advanced, Recurrent or Metastatic Malignancies
Drug: SSGJ-705
Phase 1 Recruiting 2024-05 China
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
NCT07507513 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC)
Phase 2 Recruiting 2026-03 China
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT06222671 · ClinicalTrials.gov ↗ · Axial Spondyloarthritis
Phase 2 Recruiting 2024-03 China
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
NCT07042126 · ClinicalTrials.gov ↗ · Dermatitis, Atopic
Phase 3 Recruiting 2025-08 China
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
NCT06522828 · ClinicalTrials.gov ↗ · Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
Phase 2 Recruiting 2024-10 China
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07039669 · ClinicalTrials.gov ↗ · Pulmonary Disease, Chronic Obstructive (COPD)
Phase 3 Recruiting 2025-07 China
Efficacy and Safety Study of 610 in Patients With Severe Asthma
NCT06323213 · ClinicalTrials.gov ↗ · Asthma
Phase 3 Recruiting 2024-06 China
A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
NCT07693738 · ClinicalTrials.gov ↗ · AD
Phase 1 Recruiting 2026-05 China
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
NCT07767253 · ClinicalTrials.gov ↗ · Dermatitis, Atopic
Phase 3 Not yet open 2026-09 China
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT07349329 · ClinicalTrials.gov ↗ · Axial Spondyloarthritis, Non-Radiographic
Phase 3 Not yet open 2026-03 China
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
NCT07042113 · ClinicalTrials.gov ↗ · Atopic Dermatitis
Phase 1 Not yet open 2025-07 China
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
NCT06680947 · ClinicalTrials.gov ↗ · Asthma
Phase 2 Active, closed 2024-12 China
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT06639295 · ClinicalTrials.gov ↗ · Sinusitis, Nasal Polyps
Phase 3 Active, closed 2024-11 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Sunshine Guojian Pharmaceutical (Shanghai) trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Sunshine Guojian Pharmaceutical (Shanghai) trials

15 conditions
Asthma2Dermatitis, Atopic2Systemic Lupus Erythematosus (SLE)1Metastatic Colorectal Cancer1Ankylosing Spondylitis1Locally Advanced, Recurrent or Metastatic Malignancies1Ulcerative Colitis (UC)1Axial Spondyloarthritis1Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer1Pulmonary Disease, Chronic Obstructive (COPD)1Axial Spondyloarthritis, Non-Radiographic1Atopic Dermatitis1Sinusitis1Nasal Polyps1AD1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1611

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Asthma

SponsorTrials
GlaxoSmithKline11
Sanofi6
Chiesi Farmaceutici2
Teva Branded Pharmaceutical Products R&D2
First Affiliated Hospital of Ningbo University2
Guangdong Hengrui Pharmaceutical2
Uniquity One (UNI)1
Generate Biomedicines1
Apogee Therapeutics1
Enveda Therapeutics1

Sponsors with the most current trials registered for this condition.

06

Questions about Sunshine Guojian Pharmaceutical (Shanghai) trials

How many clinical trials does Sunshine Guojian Pharmaceutical (Shanghai) sponsor?

Sunshine Guojian Pharmaceutical (Shanghai) is the lead sponsor of 16 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sunshine Guojian Pharmaceutical (Shanghai) trials recruiting?

Yes. 11 of its 16 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sunshine Guojian Pharmaceutical (Shanghai) testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Bevacizumab (1), Calcium folinate (1), Capecitabine (1), Ivonescimab (1) and Oxaliplatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.